BioNote, Inc.
KKRX:3777404,590.00
KRW
+60.00
(+1.32%)
ISIN
KR7377740006
Return %
Stock
S&P 500
1Y
-17.59
13.14
3Y
17.54
80.78
5Y
- -
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Byung-Ki Cho
- Full Time Employees
- 334
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Hwaseong-si South Korea
- IPO Date
- Dec 22, 2022
- Website
- bionote.co.kr
- Similar Companies
- Business
- BioNote, Inc. develops, manufactures, and commercializes in-vitro diagnostic products and bio-raw materials for the veterinary and life sciences industries worldwide. The company operates through two primary business divisions: Animal Diagnostics and Bio Raw Materials. Its animal diagnostic portfolio comprises point-of-care fluorescent immunoassay analyzers and quantitative biomarker test kits marketed under the Vcheck brand, including the Vcheck V200 and Vcheck V2400 systems for evaluating cardiac, inflammatory, pancreatic, renal, and endocrine biomarkers; rapid diagnostic test kits under the Anigen brand utilizing lateral flow immunochromatographic assays for screening canine, feline, bovine, swine, and avian infectious diseases; automated point-of-care molecular diagnostic systems, including the cartridge-based Vcheck M10 real-time PCR platform; compact clinical chemistry analyzers under the Vcheck C and Vcheck C1 series; automated hematology analyzers under the Vcheck H and Vcheck H6 lines; integrated urine chemistry and sediment analyzers under the Vcheck U line; and microplate enzyme-linked immunosorbent assay (ELISA) kits for high-throughput livestock disease surveillance and laboratory diagnosis. Its bio-raw materials division produces and supplies recombinant antigens, monoclonal and polyclonal antibodies, and diagnostic enzymes to global medical and veterinary diagnostic manufacturers, including its affiliate SD Biosensor. Founded in 2003 and headquartered in Hwaseong-si, South Korea, BioNote distributes its solutions across North America, Europe, Asia-Pacific, Latin America, and the Middle East, supported by regional subsidiaries including Bionote USA, Inc. In recent developments, BioNote expanded its comprehensive veterinary point-of-care platform with the commercial launch of the Vcheck M10 molecular analyzer, the Vcheck C1 biochemistry analyzer, and enhanced biomarker tests such as SDMA 2.0; accelerated its North American market penetration through strategic distribution partnerships with MWI Animal Health, Covetrus, and The Veterinary Cooperative; and strengthened its global operational footprint to expand product distribution across international veterinary hospital and laboratory networks.